Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;23(6):535-548.
doi: 10.1080/14737175.2023.2211767. Epub 2023 May 15.

Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions

Harry A Fagan  1   2 , David S Baldwin  1   2   3
Affiliations
Review

Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions

Harry A Fagan et al. Expert Rev Neurother. 2023 Jun.

Abstract

Introduction: Generalized Anxiety Disorder (GAD) is a common psychiatric condition, characterized by the presence of general apprehensiveness and excessive worry. Current management consists of a range of pharmacological and psychological treatments. However, many patients do not respond to first-line pharmacological treatments and novel anxiolytic drugs are being developed.

Areas covered: In this review, the authors first discuss the diagnostic criteria and epidemiology of GAD. The effective pharmacological treatments for GAD and their tolerability are addressed. Current consensus guidelines for treatment of GAD are discussed, and maintenance treatment, the management of treatment resistance, and specific management of older adults and children/adolescents are considered. Finally, novel anxiolytics under development are discussed, with a focus on those which have entered clinical trials.

Expert opinion: A range of effective treatments for GAD are available, particularly duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine. There is a limited evidence base to support the further pharmacological management of patients with GAD who have not responded to initial treatment. Although many novel anxiolytics have progressed to clinical trials, translation from animal models has been mostly unsuccessful. However, the potential of several compounds including certain psychedelics, ketamine, oxytocin, and agents modulating the orexin, endocannabinoid, and immune systems merits further study.

Keywords: GAD; Generalized Anxiety Disorder; novel anxiolytics; pharmacological treatment; pharmacotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Publication types

MeSH terms

LinkOut - more resources